Join to View Full Profile
200 HAWKINS DRUROLOGY - 3RCPIowa City, IA 52242
Phone+1 319-353-8771
Fax+1 319-356-3900
Dr. Odonnell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Odonnell is a Urologist based in Iowa City, IA, with a particular expertise in urologic oncology and bladder cancer. He completed his medical education at Duke University School of Medicine in 1984, followed by surgery and urology residencies at Brigham and Women's Hospital/Harvard Medical School from 1985-1991. His research has been published extensively in notable journals like European Urology, Urologic Oncology, and The Journal of Urology. This includes a significant phase 1 trial of Durvalumab for bladder cancer. He achieved the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation in 2011-2013.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Urology, 1987 - 1991- Mass General Brigham/Brigham and Women's HospitalResidency, Surgery, 1985 - 1987
Duke University School of MedicineClass of 1984
Certifications & Licensure
IA State Medical License 2000 - 2026
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Publications & Presentations
PubMed
- 33 citationsA Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasi...Noah M Hahn, Michael A O'Donnell, Jason A Efstathiou, Marianna Zahurak, Gary L Rosner
European Urology. 2023-06-01 - 36 citationsLong-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.Phani T Chevuru, Ian M McElree, Sarah L Mott, Ryan L Steinberg, Michael A O'Donnell
Urologic Oncology. 2023-03-01 - 1 citationsRe: Khyati Meghani, Lauren Folgosa Cooley, Bonnie Choy, et al. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unr...Ryan L Steinberg, Michael A O'Donnell, Vignesh T Packiam
European Urology. 2023-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
